FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
Historical Prices
From:
To:
About
ceo
Dr. Laurence A. Turka M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.rubiustx.comexchange
NASDAQ
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
CIK
0001709401
ISIN
US78116T1034
CUSIP
78116T103
Address
399 Binney Street
Phone
617 679 9600
Country
US
Employee
6
IPO Date
Jul 18, 2018
Financial Statement
Earnings
RUBY Financial Summary
CIK
0001709401
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
78116T103
ISIN
US78116T1034
Country
US
Price
0.06
Beta
2.21
Volume Avg.
99.53k
Market Cap
0
Shares
-
52-Week
0.0032-0.3763
DCF
0.15
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://www.rubiustx.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RUBY News
InvestorPlace
Feb 14, 2023
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
Rubius Therapeutics (NASDAQ: RUBY ) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company. Instead, it looks like increasing interest from traders is behind today's gains as heavy trading takes place.
InvestorPlace
Feb 7, 2023
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
Rubius Therapeutics (NASDAQ: RUBY ) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. According to a filing with the U.S. Securities and Exchange Commission (SEC), the company doesn't meet the requirements to list on The Nasdaq Stock Market.
PennyStocks
Sep 26, 2022
Hot Penny Stocks to Buy This Week? 3 to Watch Now
Which penny stocks are you watching today? The post Hot Penny Stocks to Buy This Week?
GlobeNewsWire
Sep 19, 2022
Rubius Therapeutics to Present at Guggenheim Nantucket Thera...
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.
PennyStocks
Sep 9, 2022
3 High Volume Penny Stocks To Watch Before Next Week
Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
Aug 11, 2022
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does ...
Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Seeking Alpha
Jun 19, 2022
Rubius: Poor Data, Punishing Environment, Beaten Stock
Rubius presented unconvincing data at AACR. The stock is down 80% in just 3 months.
GlobeNewsWire
Jun 1, 2022
Rubius Therapeutics to Present at the Jefferies Global Healt...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday...
